Immunotherapy of multiple myeloma

First Clinical Study of the B-Cell Maturation Antigen (BCMA) 2+1 T Cell Engager (TCE) CC-93269 in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Interim Results of a Phase 1 Multicenter Trial

(2020) Luciano J. Costa et al.   BLOOD

AMG 701 Potently Induces Anti-Multiple Myeloma (MM) Functions of T Cells and IMiDs Further Enhance Its Efficacy to Prevent MM Relapse In Vivo

(2020) Shih-Feng Cho et al.   BLOOD

Safety and efficacy of targeting CD138 with a chimeric antigen receptor for the treatment of multiple myeloma

(2019) Chuang Sun et al.   Oncotarget

Bispecific Antibodies in Hematologic Malignancies: When, to Whom, and How Should Be Best Used?

(2019) Roberta Demichelis-Gómez et al.   Current Oncology Reports

GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells

(2019) Eric L. Smith et al.   Science Translational Medicine

Mechanisms of resistance to CAR T cell therapy

(2019) Nirali N. Shah et al.   Nature Reviews Clinical Oncology

Targeting Multiple Myeloma with AMG 424, a Novel Anti-CD38/CD3 Bispecific T Cell-Recruiting Antibody Optimized for Cytotoxicity and Cytokine Release

(2019) Christina L. Zuch de Zafra et al.   CLINICAL CANCER RESEARCH

A Phase 2 Study of Pembrolizumab during Lymphodepletion after Autologous Hematopoietic Cell Transplantation for Multiple Myeloma

(2019) Anita D'Souza et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Chimeric antigen receptor T cell persistence and memory cell formation

(2019) Alexander D McLellan et al.   IMMUNOLOGY AND CELL BIOLOGY

B cell maturation antigen–specific CAR T cells are clinically active in multiple myeloma

(2019) Adam D. Cohen et al.   JOURNAL OF CLINICAL INVESTIGATION

Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma

(2019) Noopur Raje et al.   NEW ENGLAND JOURNAL OF MEDICINE

γ-secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma

(2019) Margot J. Pont et al.   BLOOD

Differences in Tumor Microenvironment Dictate T Helper Lineage Polarization and Response to Immune Checkpoint Therapy

(2019) Shiping Jiao et al.   CELL

Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma

(2019) Sagar Lonial et al.   JOURNAL OF CLINICAL ONCOLOGY

c-Jun overexpression in CAR T cells induces exhaustion resistance

(2019) Rachel C. Lynn et al.   NATURE

TIGIT immune checkpoint blockade restores CD8+T cell immunity against multiple myeloma

(2018) Camille Guillerey et al.   BLOOD

Vaccine therapy in hematologic malignancies

(2018) David Avigan et al.   BLOOD

Anti-cancer vaccine therapy for hematologic malignancies: An evolving era

(2018) Myrna R. Nahas et al.   BLOOD REVIEWS

Dysregulated IL-18 Is a Key Driver of Immunosuppression and a Possible Therapeutic Target in the Multiple Myeloma Microenvironment

(2018) Kyohei Nakamura et al.   CANCER CELL

Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies

(2018) Frederick Arce Vargas et al.   CANCER CELL

Allogeneic stem-cell transplantation for multiple myeloma: a systematic review and meta-analysis from 2007 to 2017

(2018) Xuejiao Yin et al.   Cancer Cell International

A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy

(2018) Xuexiang Du et al.   CELL RESEARCH

Effective Targeting of Multiple B-Cell Maturation Antigen–Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells

(2018) Kevin M. Friedman et al.   HUMAN GENE THERAPY

T Cells Genetically Modified to Express an Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma

(2018) Jennifer N. Brudno et al.   JOURNAL OF CLINICAL ONCOLOGY

Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia

(2018) Joseph A. Fraietta et al.   NATURE MEDICINE

Global Burden of Multiple Myeloma

(2018) Andrew J. Cowan et al.   JAMA Oncology

CrbnI391Vis sufficient to conferin vivosensitivity to thalidomide and its derivatives in mice

(2018) Emma C. Fink et al.   BLOOD

Myeloma-escape after stem cell transplantation is a consequence of T cell exhaustion and is prevented by TIGIT blockade

(2018) Simone A. Minnie et al.   BLOOD

IMiDs through loss of Ikaros and Aiolos primes myeloma cells for daratumumab mediated killing by upregulation of CD38

(2018) Pasquale L. Fedele et al.   BLOOD

Abstract LB-114: a-TIGIT antagonist antibody EOS884448 shows dual mechanism of action by restoration of T cell effector functions and preferential depletion of Treg

(2018) XAVIER LEROY et al.   CANCER RESEARCH

Abstract 1727: Antitumor activity associated with dual targeting of CD38 and programmed death-1 (PD-1) pathways in preclinical models

(2018) Natalie A. Bezman et al.   CANCER RESEARCH

Subclonal evolution in disease progression from MGUS/SMM to multiple myeloma is characterised by clonal stability

(2018) Ankit K. Dutta et al.   LEUKEMIA

Bone marrow transplantation generates T cell–dependent control of myeloma in mice

(2018) Slavica Vuckovic et al.   JOURNAL OF CLINICAL INVESTIGATION

Immunotherapy Combinations in Multiple Myeloma — Known Unknowns

(2018) Nicole J. Gormley et al.   NEW ENGLAND JOURNAL OF MEDICINE

Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma

(2018) Meletios A. Dimopoulos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Microbiota-driven interleukin-17-producing cells and eosinophils synergize to accelerate multiple myeloma progression

(2018) Arianna Calcinotto et al.   Nature Communications

Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma

(2018) Kerry S. Campbell et al.   Frontiers in Immunology

Therapeutic effects of CSF1R-blocking antibodies in multiple myeloma

(2017) Q Wang et al.   LEUKEMIA

Colony-Stimulating Factor 1 Receptor Blockade Inhibits Tumor Growth by Altering the Polarization of Tumor-Associated Macrophages in Hepatocellular Carcinoma

(2017) Jian-Yang Ao et al.   MOLECULAR CANCER THERAPEUTICS

High somatic mutation and neoantigen burden are correlated with decreased progression-free survival in multiple myeloma

(2017) A Miller et al.   Blood Cancer Journal

Therapeutic Efficacy of 4-1BB Costimulation Is Abrogated by PD-1 Blockade in a Model of Spontaneous B-cell Lymphoma

(2017) Sara J. McKee et al.   Cancer Immunology Research

Multiple myeloma

(2017) Shaji K. Kumar et al.   Nature Reviews Disease Primers

The immunotherapy era of myeloma: monoclonal antibodies, vaccines, and adoptive T-cell therapies

(2016) V. Hoyos et al.   BLOOD

Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma

(2016) J. Krejcik et al.   BLOOD

Immune responses in multiple myeloma: role of the natural immune surveillance and potential of immunotherapies

(2016) Camille Guillerey et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells

(2016) Omkar U. Kawalekar et al.   IMMUNITY

Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study

(2016) Alexander M. Lesokhin et al.   JOURNAL OF CLINICAL ONCOLOGY

T cells in multiple myeloma display features of exhaustion and senescence at the tumor site

(2016) Claudia Zelle-Rieser et al.   Journal of Hematology & Oncology

Multiple myeloma causes clonal T-cell immunosenescence: identification of potential novel targets for promoting tumour immunity and implications for checkpoint blockade

(2016) H Suen et al.   LEUKEMIA

Genomic complexity of multiple myeloma and its clinical implications

(2016) Salomon Manier et al.   Nature Reviews Clinical Oncology

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma

(2016) Meletios A. Dimopoulos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma

(2016) Antonio Palumbo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Myeloma Drug Resistance Induced by Binding of Myeloma B7-H1 (PD-L1) to PD-1

(2016) M. Ishibashi et al.   Cancer Immunology Research

Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under LenDex: a longitudinal analysis

(2015) Bruno Paiva et al.   BLOOD

Dendritic cells accumulate in the bone marrow of myeloma patients where they protect tumor plasma cells from CD8+ T-cell killing

(2015) P. Leone et al.   BLOOD

Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells

(2015) Zeguo Zhao et al.   CANCER CELL

Marrow Infiltrating Lymphocytes

(2015) Kimberly A. Noonan et al.   CANCER JOURNAL

Boosting Cancer Immunotherapy with Anti-CD137 Antibody Therapy

(2015) A. Yonezawa et al.   CLINICAL CANCER RESEARCH

Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma

(2015) G. Gorgun et al.   CLINICAL CANCER RESEARCH

Immunosurveillance and therapy of multiple myeloma are CD226 dependent

(2015) Camille Guillerey et al.   JOURNAL OF CLINICAL INVESTIGATION

Alkylating Agent Melphalan Augments the Efficacy of Adoptive Immunotherapy Using Tumor-Specific CD4+T Cells

(2015) Xiaoyun Lu et al.   JOURNAL OF IMMUNOLOGY

Targeting IL-17A in multiple myeloma: a potential novel therapeutic approach in myeloma

(2015) R H Prabhala et al.   LEUKEMIA

The pharmacology of second-generation chimeric antigen receptors

(2015) Sjoukje J. C. van der Stegen et al.   NATURE REVIEWS DRUG DISCOVERY

Adoptive transfer of activated marrow-infiltrating lymphocytes induces measurable antitumor immunity in the bone marrow in multiple myeloma

(2015) Kimberly A. Noonan et al.   Science Translational Medicine

Immunomodulatory molecule PD-L1 is expressed on malignant plasma cells and myeloma-propagating pre-plasma cells in the bone marrow of multiple myeloma patients

(2015) S Yousef et al.   Blood Cancer Journal

Serum levels of soluble programmed death ligand 1 predict treatment response and progression free survival in multiple myeloma

(2015) Liang Wang et al.   Oncotarget

T-cell Exhaustion in Multiple Myeloma Relapse after Autotransplant: Optimal Timing of Immunotherapy

(2015) D. J. Chung et al.   Cancer Immunology Research

Combined immune checkpoint protein blockade and low dose whole body irradiation as immunotherapy for myeloma

(2015) Weiqing Jing et al.   Journal for ImmunoTherapy of Cancer

Etanercept plus Topical Corticosteroids as Initial Therapy for Grade One Acute Graft-Versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation

(2014) Erin Gatza et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

CD28-mediated pro-survival signaling induces chemotherapeutic resistance in multiple myeloma

(2014) M. E. Murray et al.   BLOOD

Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy

(2014) Jens G. Lohr et al.   CANCER CELL

Targeting Tumor-Associated Macrophages with Anti-CSF-1R Antibody Reveals a Strategy for Cancer Therapy

(2014) Carola H. Ries et al.   CANCER CELL

Combination Immunotherapy after ASCT for Multiple Myeloma Using MAGE-A3/Poly-ICLC Immunizations Followed by Adoptive Transfer of Vaccine-Primed and Costimulated Autologous T Cells

(2014) Aaron P. Rapoport et al.   CLINICAL CANCER RESEARCH

New insights into cancer immunoediting and its three component phases—elimination, equilibrium and escape

(2014) Deepak Mittal et al.   CURRENT OPINION IN IMMUNOLOGY

Serial exome analysis of disease progression in premalignant gammopathies

(2014) S Zhao et al.   LEUKEMIA

Potential relationship and clinical significance of miRNAs and Th17 cytokines in patients with multiple myeloma

(2014) Yanjie Li et al.   LEUKEMIA RESEARCH

Vaccination with Dendritic Cell/Tumor Fusions following Autologous Stem Cell Transplant Induces Immunologic and Clinical Responses in Multiple Myeloma Patients

(2013) J. Rosenblatt et al.   CLINICAL CANCER RESEARCH

T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment

(2013) Joel Crespo et al.   CURRENT OPINION IN IMMUNOLOGY

Programmed Death Receptor-1/Programmed Death Receptor Ligand-1 Blockade after Transient Lymphodepletion To Treat Myeloma

(2013) T. J. Kearl et al.   JOURNAL OF IMMUNOLOGY

Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms

(2013) B A Walker et al.   LEUKEMIA

Signatures of mutational processes in human cancer

(2013) Ludmil B. Alexandrov et al.   NATURE

Lenalidomide plus Dexamethasone for High-Risk Smoldering Multiple Myeloma

(2013) María-Victoria Mateos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells

(2013) J. Kronke et al.   SCIENCE

The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins

(2013) G. Lu et al.   SCIENCE

The IL-17 Differentiation Pathway and Its Role in Transplant Outcome

(2012) Jonathan S. Serody et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Lenalidomide enhances anti-myeloma cellular immunity

(2012) Katarina Luptakova et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

What lessons can be learned from γδ T cell-based cancer immunotherapy trials?

(2012) Jean-Jacques Fournié et al.   Cellular & Molecular Immunology

Molecular pathogenesis of multiple myeloma and its premalignant precursor

(2012) W. Michael Kuehl et al.   JOURNAL OF CLINICAL INVESTIGATION

Immunosuppressive Effects of Multiple Myeloma Are Overcome by PD-L1 Blockade

(2011) William H.D. Hallett et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Long-term prognostic significance of response in multiple myeloma after stem cell transplantation

(2011) J. Martinez-Lopez et al.   BLOOD

Harnessing natural killer T (NKT) cells in human myeloma: Progress and challenges

(2011) Madhav V. Dhodapkar et al.   CLINICAL IMMUNOLOGY

PD-1 Blockade by CT-011, Anti-PD-1 Antibody, Enhances Ex Vivo T-cell Responses to Autologous Dendritic Cell/Myeloma Fusion Vaccine

(2011) Jacalyn Rosenblatt et al.   JOURNAL OF IMMUNOTHERAPY

Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion

(2011) R. D. Schreiber et al.   SCIENCE

Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma

(2010) J. Rosenblatt et al.   BLOOD

The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody

(2010) D. M. Benson et al.   BLOOD

Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma

(2010) R. H. Prabhala et al.   BLOOD

Natural killer cell activity in monoclonal gammopathies: Relation to disease activity

(2010) A. Österborg et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study

(2010) Michele Cavo et al.   LANCET

Increased Level of both CD4+FOXP3+ Regulatory T Cells and CD14+HLA-DR−/low Myeloid-Derived Suppressor Cells and Decreased Level of Dendritic Cells in Patients with Multiple Myeloma

(2010) M. K. Brimnes et al.   SCANDINAVIAN JOURNAL OF IMMUNOLOGY

Idiotype-pulsed antigen presenting cells following autologous transplantation for multiple myeloma may be associated with prolonged survival

(2009) Martha Q. Lacy et al.   AMERICAN JOURNAL OF HEMATOLOGY

Alterations in the antigen processing-presenting machinery of transformed plasma cells are associated with reduced recognition by CD8+ T cells and characterize the progression of MGUS to multiple myeloma

(2009) V. Racanelli et al.   BLOOD

Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study

(2009) O. Landgren et al.   BLOOD

Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis

(2009) Y. Zheng et al.   BLOOD

Role of autologous and allogeneic stem cell transplantation in myeloma

(2009) W I Bensinger   LEUKEMIA

Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma

(2009) H Quach et al.   LEUKEMIA

AID-Dependent Activation of a MYC Transgene Induces Multiple Myeloma in a Conditional Mouse Model of Post-Germinal Center Malignancies

(2008) Marta Chesi et al.   CANCER CELL

The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells

(2008) Christine Galustian et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Therapeutic Antitumor Efficacy of Anti-CD137 Agonistic Monoclonal Antibody in Mouse Models of Myeloma

(2008) O. Murillo et al.   CLINICAL CANCER RESEARCH

The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells

(2008) Xin Yu et al.   NATURE IMMUNOLOGY